Targeting Chemokines for Acute Lymphoblastic Leukemia Therapy

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2021 Mar 21

PMID 33743810

Citations 22

Authors

Zixi Hong

Zimeng Wei

Tian Xie

Lin Fu

Jiaxing Sun

Fuling Zhou

Muhammad Jamal

Qiuping Zhang

Liang Shao

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cytokines and adhesion molecules in its microenvironment. Chemokines are chemotactic cytokines that regulate migration, positioning and interactions of cells. Many chemokine axes such as CXCL12/CXCR4 and CCL25/CCR9 have been proved to play important roles in leukemia microenvironment and further affect ALL outcomes. In this review, we summarize the chemokines that are involved in ALL progression and elaborate on their roles and mechanisms in leukemia cell proliferation, infiltration, drug resistance and disease relapse. We also discuss the potential of targeting chemokine axes for ALL treatments, since many related inhibitors have shown promising efficacy in preclinical trials, and some of them have entered clinical trials.

Citing Articles

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Stajer M, Horacek J, Kupsa T, Zak P J Appl Biomed. 2025; 22(4):165-184.

PMID: 40033805 DOI: 10.32725/jab.2024.024.

Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.

Ma J, Yan C, Jia X, Zhu H, Yan J, Liu M Ann Hematol. 2024; 104(1):57-63.

PMID: 39692783 DOI: 10.1007/s00277-024-06132-w.

In Vitro Purging of Acute Lymphoblastic Leukemia (B-ALL) Cells with the Use of PTL, DMAPT, or PU-H71.

Ortiz-Reyes A, Garcia-Sanchez S, Serrano M, Nunez-Enriquez J, Alvarado-Moreno J, Montesinos J Int J Mol Sci. 2024; 25(21).

PMID: 39519261 PMC: 11546800. DOI: 10.3390/ijms252111707.

Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis.

Zheng L, Pan C, Ma D, Shang Q, Hu T, Zhang T Front Pharmacol. 2024; 15:1393482.

PMID: 39081954 PMC: 11286583. DOI: 10.3389/fphar.2024.1393482.

Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis.

Li Z, Lu H, Zhang Y, Lv J, Zhang Y, Xu T Cancer Sci. 2024; 115(10):3305-3319.

PMID: 39073190 PMC: 11447900. DOI: 10.1111/cas.16295.

References

Campbell D, Butcher E . Intestinal attraction: CCL25 functions in effector lymphocyte recruitment to the small intestine. J Clin Invest. 2002; 110(8):1079-81. PMC: 150808. DOI: 10.1172/JCI16946. View

Arnaud M, Vallee A, Robert G, Bonneau J, Leroy C, Varin-Blank N . CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling. Blood. 2015; 126(15):1802-12. DOI: 10.1182/blood-2015-02-628560. View

Welschinger R, Liedtke F, Basnett J, Dela Pena A, Juarez J, Bradstock K . Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol. 2012; 41(3):293-302.e1. DOI: 10.1016/j.exphem.2012.11.004. View

Bodart V, Anastassov V, Darkes M, Idzan S, Labrecque J, Lau G . Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol. 2009; 78(8):993-1000. DOI: 10.1016/j.bcp.2009.06.010. View

Catusse J, Wollner S, Leick M, Schrottner P, Schraufstatter I, Burger M . Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol. 2010; 225(3):792-800. DOI: 10.1002/jcp.22284. View

Qiuping Z, Qun L, Chunsong H, Xiaolian Z, Baojun H, Mingzhen Y . Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. Cancer Res. 2003; 63(19):6469-77. View

Woollard S, Kanmogne G . Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther. 2015; 9:5447-68. PMC: 4598208. DOI: 10.2147/DDDT.S90580. View

Qiuping Z, Jei X, Youxin J, Wei J, Chun L, Jin W . CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res. 2004; 64(20):7579-87. DOI: 10.1158/0008-5472.CAN-04-0641. View

Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N . Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011; 25(8):1314-23. PMC: 3135709. DOI: 10.1038/leu.2011.76. View

10.

Ma Z, Zhao X, Deng M, Huang Z, Wang J, Wu Y . Bone Marrow Mesenchymal Stromal Cell-Derived Periostin Promotes B-ALL Progression by Modulating CCL2 in Leukemia Cells. Cell Rep. 2019; 26(6):1533-1543.e4. DOI: 10.1016/j.celrep.2019.01.034. View

11.

Dolin R . A new class of anti-HIV therapy and new challenges. N Engl J Med. 2008; 359(14):1509-11. DOI: 10.1056/NEJMe0806598. View

12.

Redondo-Munoz J, Garcia-Pardo A, Teixido J . Molecular Players in Hematologic Tumor Cell Trafficking. Front Immunol. 2019; 10:156. PMC: 6372527. DOI: 10.3389/fimmu.2019.00156. View

13.

Morrison S, Spradling A . Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008; 132(4):598-611. PMC: 4505728. DOI: 10.1016/j.cell.2008.01.038. View

14.

Li W, Jiang Z, Li T, Wei X, Zheng Y, Wu D . Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes. Mol Cancer. 2015; 14:26. PMC: 4350611. DOI: 10.1186/s12943-014-0285-x. View

15.

Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink F . High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001; 115(3):545-53. DOI: 10.1046/j.1365-2141.2001.03164.x. View

16.

Peled A, Klein S, Beider K, Burger J, Abraham M . Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine. 2018; 109:11-16. DOI: 10.1016/j.cyto.2018.02.020. View

17.

Chamorro S, Vela M, Franco-Villanueva A, Carramolino L, Gutierrez J, Gomez L . Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs. 2014; 6(4):1000-12. PMC: 4171004. DOI: 10.4161/mabs.29063. View

18.

Ahmadzadeh A, Kast R, Ketabchi N, Shahrabi S, Shahjahani M, Jaseb K . Regulatory effect of chemokines in bone marrow niche. Cell Tissue Res. 2015; 361(2):401-10. DOI: 10.1007/s00441-015-2129-4. View

19.

Hodby K, Marks D . Recent Advances in the Management of Acute Lymphoblastic Leukaemia. Curr Treat Options Oncol. 2020; 21(3):23. DOI: 10.1007/s11864-020-0712-8. View

20.

Sison E, Rau R, Mcintyre E, Li L, Small D, Brown P . MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol. 2013; 160(6):785-97. PMC: 4005340. DOI: 10.1111/bjh.12205. View